Global Angiotensin Receptor Blockers (ARBs) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Angiotensin Receptor Blockers (ARBs) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists, AT1 receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
Angiotensin Receptor Blockers (ARBs) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Angiotensin Receptor Blockers (ARBs) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hypertension and Cardiovascular Diseases are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Angiotensin Receptor Blockers (ARBs) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Angiotensin Receptor Blockers (ARBs) key manufacturers include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. Pfizer, Novartis, Merck are top 3 players and held % sales share in total in 2022.
Angiotensin Receptor Blockers (ARBs) can be divided into Valsartan, Telmisartan, Losartan and Irbesartan, etc. Valsartan is the mainstream product in the market, accounting for % sales share globally in 2022.
Angiotensin Receptor Blockers (ARBs) is widely used in various fields, such as Hypertension, Cardiovascular Diseases, Kidney Diseases and Other, etc. Hypertension provides greatest supports to the Angiotensin Receptor Blockers (ARBs) industry development. In 2022, global % sales of Angiotensin Receptor Blockers (ARBs) went into Hypertension filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Angiotensin Receptor Blockers (ARBs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Segment by Type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Angiotensin Receptor Blockers (ARBs) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Angiotensin Receptor Blockers (ARBs), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Angiotensin Receptor Blockers (ARBs) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Angiotensin Receptor Blockers (ARBs) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Angiotensin Receptor Blockers (ARBs) introduction, etc. Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Angiotensin Receptor Blockers (ARBs) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Angiotensin Receptor Blockers (ARBs) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Angiotensin Receptor Blockers (ARBs) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hypertension and Cardiovascular Diseases are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Angiotensin Receptor Blockers (ARBs) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Angiotensin Receptor Blockers (ARBs) key manufacturers include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. Pfizer, Novartis, Merck are top 3 players and held % sales share in total in 2022.
Angiotensin Receptor Blockers (ARBs) can be divided into Valsartan, Telmisartan, Losartan and Irbesartan, etc. Valsartan is the mainstream product in the market, accounting for % sales share globally in 2022.
Angiotensin Receptor Blockers (ARBs) is widely used in various fields, such as Hypertension, Cardiovascular Diseases, Kidney Diseases and Other, etc. Hypertension provides greatest supports to the Angiotensin Receptor Blockers (ARBs) industry development. In 2022, global % sales of Angiotensin Receptor Blockers (ARBs) went into Hypertension filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Angiotensin Receptor Blockers (ARBs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Segment by Type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segment by Application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Angiotensin Receptor Blockers (ARBs) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Angiotensin Receptor Blockers (ARBs), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Angiotensin Receptor Blockers (ARBs) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Angiotensin Receptor Blockers (ARBs) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Angiotensin Receptor Blockers (ARBs) introduction, etc. Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Angiotensin Receptor Blockers (ARBs) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices